Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 655-657

  Gould, Virginia C ^a   Okazaki, Aki ^a   Avison, Matthew B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SMEJ PROTEIN; SMEK PROTEIN; SMEZ PROTEIN; SULFAMETHOXAZOLE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; FRAMESHIFT MUTATION; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; OPERON; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CIPROFLOXACIN; GENE EXPRESSION; GENES, MDR; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OFLOXACIN; STENOTROPHOMONAS MALTOPHILIA; TETRACYCLINE;

EID: 84872038448     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01020-12     Document Type: Article

References (17)

1. Looney WJ, Narita M, Mühlemann K. 2009. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9:312-323.
2. Ryan RP, Monchy S, Cardinale M, Taghavi S, Crossman L, Avison MB, Berg G, van der Lelie D, Dow JM. 2009. The versatility and adaptation of bacteria from the genus Stenotrophomonas. Nat. Rev. Microbiol. 7:514-525.
3. Gould VC, Okazaki A, Avison MB. 2006. β-Lactam resistance and β-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J. Antimicrob. Chemother. 57:199-203.
4. Okazaki A, Avison MB. 2008. Induction of L1 and L2 β-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator. Antimicrob. Agents Chemother. 52:1525-1528.
5. Lambert T, Ploy MC, Denis F, Courvalin P. 1999. Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 43:2366-2371.
6. Li XZ, Zhang L, McKay GA, Poole K. 2003. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 51:803-811.
7. Okazaki A, Avison MB. 2007. Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 51:359-360.
8. Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, Saunders D, Arrowsmith C, Carver T, Peters N, Adlem E, Kerhornou A, Lord A, Murphy L, Seeger K, Squares R, Rutter S, Quail MA, Rajandream MA, Harris D, Churcher C, Bentley SD, Parkhill J, Thomson NR, Avison MB. 2008. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 9:R74.
9. Zhang L, Li XZ, Poole K. 2001. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:3497-3503.
10. Alonso A, Martínez JL. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44:3079-3086.
11. Farrell DJ, Sader HS, Jones RN. 2010. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 54:2735-2737.
12. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Gould VC, Avison MB. 2006. SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J. Antimicrob. Chemother. 57:1070-1076.
14. CLSI. 2012. Performance standards for antimicrobial susceptibility testing. 22nd informational supplement. M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. 2007. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 13:559-565.
16. Millar FA, Simmonds NJ, Hodson ME. 2009. Trends in pathogens colonizing the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J. Cyst. Fibros. 8:386-391.
17. Bals R, Hubert D, Tümmler B. 2011. Antibiotic treatment of CF lung disease: from bench to bedside. J. Cyst. Fibros. 10(Suppl 2):S146-S151.